Why Submit to bioRxiv? The Priority-Claim Case

Why submit to bioRxiv? Because posting a preprint puts a date-stamped, citable record of a finding into the scientific record within about 72 hours, at no cost, months or years before journal peer review concludes — locking in priority of discovery and starting the citation clock early. The trade-off, for early-career researchers weighing careers built on tenure and grant panels, is that some hiring committees still discount work that has not been certified by peer review. This piece weighs that trade-off directly.

A preprint is a complete, unpublished research manuscript posted to a public server before or during formal journal peer review, allowing other scientists to read, cite, and comment on it immediately. bioRxiv, launched in 2013 by Cold Spring Harbor Laboratory and now operated by the nonprofit openRxiv, is the dominant preprint server for the life sciences.

• How preprinting establishes priority and a citation head-start
• bioRxiv submission requirements, cost, and screening
• Is bioRxiv a good journal? Peer review, impact factor, and the stigma question
• Answer-first: what researchers ask about submitting to bioRxiv
• Implications for hiring committees and research offices

How preprinting establishes priority and a citation head-start

The single strongest career argument for preprinting is priority. A bioRxiv preprint receives a Crossref-registered DOI and a public timestamp the moment it clears screening, which typically happens within 72 hours of submission, according to bioRxiv’s own FAQ. In fields where being scooped is a genuine professional risk, that timestamp is evidence of when a discovery was first reported — independent of how long the eventual journal review takes.

Citation accrual starts on the same clock. A preprint is indexed by Google Scholar, Crossref, Europe PMC, and the Preprint Citation Index that feeds into Clarivate’s Web of Science, so citations to the preprint can begin accumulating while the manuscript is still moving through peer review at a journal. For an early-career researcher assembling a tenure dossier or a grant CV on a tight timeline, that head-start is not marginal: it is often the difference between listing a paper as “in preparation” and listing a citable, DOI-bearing output.

Funders increasingly treat this as a feature, not a workaround. The US National Institutes of Health states in its policy on interim research products that it “encourages investigators to use interim research products, such as preprints, to speed the dissemination and enhance the rigor of their work,” and explicitly permits preprints to be cited in NIH grant applications. UK Research and Innovation and cOAlition S funders have adopted comparable positions, treating preprints as legitimate evidence of research activity rather than as a substitute for eventual peer-reviewed publication.

bioRxiv submission requirements, cost, and screening

The practical barrier to entry is low. bioRxiv charges no submission fee, accepts a single PDF or separate text and figure files, and requires the manuscript to be a complete research article rather than a partial dataset, protocol, or narrative review. Authors retain copyright and choose their own reuse licence, from a restrictive “no reuse without permission” option through to CC-BY or CC0.

Every submission passes through screening before posting:

• Checked for plagiarism and non-scientific content
• Restricted to appropriate article types (complete research articles, not case reports, editorials, or theses)
• Screened for material that could endanger public health, including dual-use research of concern
• Assigned to one of roughly 25 subject categories for indexing and alert feeds
• Author-supplied funder details captured against Research Organization Registry (ROR) identifiers, so grant provenance is machine-readable from day one

Clinical research and most epidemiology work is routed to bioRxiv’s sister server, medRxiv, rather than bioRxiv itself. Once posted, the manuscript can be revised at any point up to journal publication, and a growing list — 249 journals and counting, per bioRxiv — accepts direct submission straight from the bioRxiv author area, removing a re-formatting step that otherwise costs authors real time.

Is bioRxiv a good journal? Peer review, impact factor, and the stigma question

bioRxiv is not a journal and carries no Impact Factor — bioRxiv’s own FAQ is explicit on this point, and treating “is bioRxiv a good journal” as the right question misframes what the server does. bioRxiv is a distribution layer that sits before certification, not a substitute for it. Preprints are not peer-reviewed, are not copyedited, and carry a visible statement — on the web page and stamped on the PDF — that the content has not been certified by peer review.

That distinction is exactly where residual stigma persists. Some hiring and tenure committees, particularly on panels weighted toward clinical or highly competitive biomedical fields, still discount preprints relative to peer-reviewed articles when scoring a CV, on the reasoning that unreviewed claims may not survive scrutiny. A 2026 analysis in Nature — marking bioRxiv’s first thirteen years — found the server now serves roughly four million article downloads a month, evidence that the research community has normalised reading preprints even where evaluation culture has been slower to follow.

The realistic position is neither “preprints replace journals” nor “preprints are worthless until reviewed.” A preprint is a citable interim research product that starts priority and citation clocks early, while journal publication remains the certification event most evaluators still weight most heavily. The two are complementary outputs of the same manuscript, not competing ones.

Answer-first: what researchers ask about submitting to bioRxiv

Should I submit to bioRxiv?

For most life-science manuscripts not restricted by an intended journal’s embargo policy, submitting to bioRxiv is low-risk and low-cost: it is free, reversible in framing (a preprint can still go to almost any major journal afterward), and establishes priority and a citable record months before formal publication would otherwise exist.

Is bioRxiv considered a journal?

No. bioRxiv is a preprint server, not a journal — it has no editorial board issuing acceptance decisions, no peer review before posting, and no Impact Factor, because Impact Factor is calculated only for indexed journals with a certified publication record.

What are the disadvantages of preprints?

The main disadvantages are that unreviewed errors can circulate publicly, media may misreport preliminary findings as settled science, and some evaluators still discount unreviewed work — though bioRxiv’s screening process filters for plagiarism and non-scientific content before posting, which narrows but does not eliminate this risk.

What is the point of publishing a preprint?

The point is speed and openness: a preprint shares results while they are still novel, invites feedback from the wider community before formal review, and gives funders, hiring committees, and collaborators a citable, timestamped output during the months a manuscript would otherwise sit silently in journal review.

Implications for hiring committees and research offices

Research administration offices increasingly need an explicit institutional position on preprints, rather than leaving the judgement to individual panel members. Funder policy has moved faster than evaluation culture: NIH, UKRI, and cOAlition S signatories already accept preprints as legitimate interim outputs, so an institution that still penalises preprinted work in internal review is applying a stricter standard than the funders whose own mandates it must meet.

A workable institutional line treats a bioRxiv preprint as evidence of productivity and priority, distinct from and not a substitute for the peer-reviewed version. Many preprints now also carry a CRediT contributor-role statement, disclosing who did what on the manuscript before formal publication — giving hiring committees more, not less, information at the preprint stage than a bare author list would. Committees that build this distinction into their guidance — crediting the preprint for priority and productivity while still weighting the peer-reviewed record for certification — give researchers the full benefit of preprinting without treating unreviewed claims as equivalent to reviewed ones.

For early-career researchers, the calculus is straightforward: the cost of preprinting is close to zero, the upside is a genuine priority claim and citation head-start backed by funder policy, and the residual risk sits in a shrinking set of evaluation contexts that have not yet caught up with mandates already in force.